Healing Osteoarthritic Joints in the Wrist With Adult ADRCs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-21

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, randomized, double-blinded, active controlled, single site safety and efficacy study in subjects suffering from chronic wrist osteoarthritis comparing a single ADRC injection generated with the Transpose® RT system into the wrist.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Clinical Efficacy of Autologous Adipose Tissue Derived ADSCSs in Treatment of Osteoarthritis (OA)

NCT05484856

Osteoarthritis, Knee

COMPLETED PHASE1/PHASE2

Injection of Autologous Adipose Tissue for Treatment of Osteoarthritis in the Knee

NCT03399630

Osteo Arthritis Knee

COMPLETED NA

Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis

NCT04043819

Knee Osteoarthritis

UNKNOWN PHASE1

Cell-free Stem Cell-derived Extract Formulation for Knee Osteoarthritis

NCT04971798

Osteoarthritis, Knee

NOT_YET_RECRUITING EARLY_PHASE1

Intra-articular Adipose Tissue Injections for Osteoarthritis

NCT03242707

Osteoarthritis, Knee

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The focus of this study is to investigate the therapeutic benefit of autologous adipose-derived regenerative cells in patients with wrist arthritis. The hypothesis of this trial is that the use of adult-adipose derived regenerative cells as a treatment of wrist arthritis will induce healing and decrease pain compared to the control group. With adult-adipose derived regenerative cell administration, the medical practitioner would anticipate a reduction in inflammation, acceleration in healing, decreased pain in patients post procedure, and increased function and strength in the affected wrist. Currently, no clinical studies have been constructed to determine the efficacy of ADRCs in wrist arthritis patients.

Subjects will fall into two categories: treatment group (20) and control group (20 subjects). The treatment group will undergo a small liposuction procedure and receive wrist osteoarthritis treatment with an ultrasound-guided injection of 5 ml adipose-derived stem cells (ADSCs) into the wrist. The control group will receive a 5 ml cortisone injection into the wrist.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis of the Wrist

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

It is a double-blinded trial in which the subjects, investigator and radiologists are blinded to treatment assignment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adipose Derived Regenerative Cell group

Subjects in the treated group will receive an Adipose derived regenerative cells (ADRCs) injection into the wrist using a fluoroscopic-guided injection .

Group Type EXPERIMENTAL

adipose-derived stem cell injection

Intervention Type DEVICE

5 ml injection of adipose derived stem cells

Corticosteroid group

Subjects in the active control group will receive a corticosteroid injection into the wrist using a fluoroscopic-guided injection.

Group Type ACTIVE_COMPARATOR

Corticosteroid injection

Intervention Type DRUG

5 ml injection of corticosteroid

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

adipose-derived stem cell injection

5 ml injection of adipose derived stem cells

Intervention Type DEVICE

Corticosteroid injection

5 ml injection of corticosteroid

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females ages: 18 - 75.
2. Clinical symptoms consistent with wrist osteoarthritis.
3. Diagnosed with wrist osteoarthritis on radiographs.
4. The ability of subjects to give appropriate consent or have a legally authorized representative available.

Exclusion Criteria

1. Subjects who have a documented history or presence of inflammatory arthritis, rheumatoid arthritis, severe osteoporosis, sepsis and chondrocalcinosis in the wrist
2. Subjects who have a documented diagnosis of carpal tunnel syndrome.
3. Insufficient amount of subcutaneous tissue to allow recovery of 100ml of lipoaspirate
4. History of systemic malignant or local neoplasms on affected limb within last 5 years
5. Subject is receiving immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.)
6. Subjects who have received a corticosteroid injection in the treatment site
7. Subjects on an active regimen of chemotherapy
8. Allergy to sodium citrate of any "caine" type of local anesthetic
9. Subjects pregnant or breast feeding
10. Subject is in the opinion of the Investigator or designee, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason. This includes completion of patient reported outcome instruments
11. Subjects who have document allergy to radiographic guidance agents.
12. Subject is currently participating in another clinical trial that has not yet completed its primary endpoint
13. History of tobacco use within the last 3 months
14. Subjects with documented with a history of alcohol or drug abuse
15. Subjects who have a documented history of HIV, Hepatitis B, and Hepatitis C
16. Subject is part of a vulnerable population who, in the judgment of the investigator, is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include: Individuals with mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No